Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P622: Child outcome in IBD pregnancy: early vs. late discontinuation of IFX therapy

ECCO '19 Copenhagen

Year: 2019
Authors:

B. Truta*1, T. Bayless1, J. Canner1, S. Bashar1

1Johns Hopkins University, Baltimore, USA

P623: Colorectal cancer, colectomy rates and inflammatory bowel disease activity following liver transplantation in primary sclerosing cholangitis: a systematic review and meta-analysis

ECCO '19 Copenhagen

Year: 2019
Authors:

T. Thomas*1, R. Cooney2, T. Iqbal2,3, S. Ghosh2,3, J. Ferguson3,4, G. Hirschfield5, P. Trivedi3,4,6,7

1University of Oxford, Translational Gastroenterology Unit, Oxford, UK, 2University Hospitals Birmingham, Birmingham, UK, 3National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre (BRC), Birmingham, UK, 4University Hospitals Birmingham, Liver Unit, Birmingham, UK, 5University Health Network, University of Toronto, Toronto Centre for Liver Disease, Toronto, Canada, 6University of Birmingham, Institute of Immunology and Immunotherapy, Birmingham, UK, 7University of Birmingham, Institute of Applied Health Research, Birmingham, UK

P624: Factors that may influence the development of anti-drug antibodies to adalimumab

ECCO '19 Copenhagen

Year: 2019
Authors:

W. Reinisch*1, I. Rauter2, L. Chen3, M. Gessner3, G. Fanjiang3

1Medical University of Vienna, Vienna, Austria, 2Amgen (Europe) GmbH, Rotkreuz, Switzerland, 3Amgen Inc., Thousand Oaks, USA

P625: Head-to-head comparison of three stool calprotectin tests for home use

ECCO '19 Copenhagen

Year: 2019
Authors:

S-M. Haisma*1, A. Galaurchi2, S. Almahwzi2, J. Adekanmi Balogun2, A. Muller Kobold3, P. van Rheenen1

1University Medical Center Groningen, Paediatric Gastroenterology, Groningen, The Netherlands, 2University Medical Center Groningen, Groningen, The Netherlands, 3University Medical Center Groningen, Laboratory Medicine, Groningen, The Netherlands

P626: Higher discontinuation rates of anti-TNF therapy in elderly IBD patients compared with a younger age group: results from a prospective registry

ECCO '19 Copenhagen

Year: 2019
Authors:

L. Smits*1, M. de Jong1, N. den Broeder1, M. Russel2, T. Römkens3, R. West4, J. Jansen5, F. Hoentjen1

1Radboud University Medical Center, Gastroenterology and Hepatology, Nijmegen, The Netherlands, 2Medisch Spectrum Twente, Gastroenterology and Hepatology, Enschede, The Netherlands, 3Jeroen Bosch Ziekenhuis, Gastroenterology and Hepatology, 's Hertogenbosch, The Netherlands, 4Franciscus Gasthuis and Vlietland, Gastroenterology and Hepatology, Rotterdam, The Netherlands, 5Onze Lieve Vrouwe Gasthuis, Gastroenterology and Hepatology, Amsterdam, The Netherlands

P627: Stopping anti-tumour necrosis factor (TNF) therapy in patients with perianal Crohn’s disease: Results from a population-based study

ECCO '19 Copenhagen

Year: 2019
Authors:

W. Y. Mak*1, W. Tang1, F. K. L. Chan1, W. K. Leung2, M. K. K. Li3, F. H. Lo4, C. K. M. Ng5, A. S. F. Sze6, C. M. Leung7, S. W. C. Tsang8, E. H. S. Shan9, K. H. Chan10, B. C. Y. Lam11, A. J. Hui12, W. H. Chow13, J. J. Y. Sung1, S. C. Ng1

1The Chinese University of Hong Kong, Medicine and Therapeutics, Hong Kong, Hong Kong, 2The University of Hong Kong, Medicine, Hong Kong, Hong Kong, 3Tuen Mun Hospital, Medicine and Geriatrics, Hong Kong, Hong Kong, 4United Christian Hospital, Medicine and Geriatrics, Hong Kong, Hong Kong, 5Princess Margaret Hospital, Medicine and Geriatrics, Hong Kong, Hong Kong, 6Queen Elizabeth Hospital, Medicine, Hong Kong, Hong Kong, 7Pamela Youde Nethersole Eastern Hospital, Medicine, Hong Kong, Hong Kong, 8Tseung Kwan O Hospital, Medicine, Hong Kong, Hong Kong, 9Caritas Medical Centre, Medicine and Geriatrics, Hong Kong, Hong Kong, 10North District Hospital, Medicine, Hong Kong, Hong Kong, 11Kwong Wah Hospital, Medicine and Geriatrics, Hong Kong, Hong Kong, 12Alice Ho Miu Ling Nethersole Hospital, Medicine and Therapeutics, Hong Kong, Hong Kong, 13Yan Chai Hospital, Medicine, Hong Kong, Hong Kong

P628: Long-term outcomes with transmural healing vs. mucosal healing in Crohn’s disease: time for new treatment goals ?

ECCO '19 Copenhagen

Year: 2019
Authors:

F. Castiglione1, N. Imperatore*1, A. Testa1, G. D. De Palma2, O. M. Nardone1, L. Pellegrini1, N. Caporaso1, A. Rispo1

1Gastroenterology, School of Medicine Federico II of Naples, Naples, Italy, 2Surgical Endoscopy, School of Medicine Federico II of Naples, Naples, Italy

P629: The initial trough concentration at 36 h after starting tacrolimus is important for the personalised medicine strategy in patients with ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

N. Hida*1, K. Watanabe2, T. Miyazaki1, Y. Yokoyama2, M. Kawai1, T. Takagawa1, K. Kamikozuru1, T. Sato2, K. Fujimoto1, R. Koshiba1, K. Kojima1, S. Nakamura1

1Hyogo College of Medicine, Department of Inflammatory Bowel Disease, Nishinomiya, Hyogo, Japan, 2Hyogo College of Medicine, Department of Intestinal Inflammation Research, Nishinomiya, Hyogo, Japan

P630: A non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients

ECCO '19 Copenhagen

Year: 2019
Authors:

R. Walmsley*1, A. McCombie2, M. Barclay2, N. Visesio1, C. Ho3, S. Brown4, K. Rosser5, S. Inns4, A. Gray6, H. Regenbrecht6, T. Langlotz6, M. Schultz6

1Waitemata District Health Board, Gastroenterology, Auckland, New Zealand, 2University of Otago, Medicine, Christchurch, New Zealand, 3Southern District Health Board, Gastroenterology, Dunedin, New Zealand, 4Hutt Valley District Health Board, Gastroenterology, Hutt, New Zealand, 5Canterbury District Health Board, Gastroenterology, Christchurch, New Zealand, 6University of Otago, Gastroenterology, Dunedun, New Zealand

P631: Development and validation of a clinical scoring tool for predicting treatment outcomes with vedolizumab in patients with ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

P. S. Dulai*1, S. Singh1, N. Vande Casteele1, J. Meserve1, A. Winters2, S. Chablaney2, S. Aniwan3, P. Shashi4, G. Kochhar4, A. Weiss5, J. L. Koliani-Pace6, Y. Gao7, B. S. Boland1, J. T. Chang1, D. Faleck2, R. Hirten2, R. Ungaro2, D. Lukin5, K. Sultan7, D. Hudesman8, S. Chang8, M. Bohm9, S. Varma9, M. Fischer9, E. Shmidt10, A. Swaminath11, N. Gupta12, M. Rosario13, V. Jairath14, L. Guizzetti15, B. G. Feagan14, C. A. Siegel6, B. Shen4, S. Kane3, E. V. Loftus Jr3, W. J. Sandborn1, B. E. Sands2, J-F. Colombel2, K. Lasch13, C. Cao13

1University of California San Diego, La Jolla, CA, USA, 2Icahn School of Medicine at Mount Sinai, New York, NY, USA, 3Mayo Clinic, Rochester, MN, USA, 4Cleveland Clinic Foundation, Cleveland, OH, USA, 5Montefiore Medical Center, New York, NY, USA, 6Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA, 7North Shore University Hospital, Manhasset, NY, USA, 8New York University (NYU), New York, NY, USA, 9Indiana University, Indianapolis, IN, United States, 10University of Minnesota, Minneapolis, MN, United States, 11Lenox Hill Hospital, New York, NY, United States, 12University of Mississippi, Jackson, MS, United States, 13Takeda Pharmaceuticals U.S.A., Inc., Deerfield, IL, United States, 14University of Western Ontario, London, ON, Canada, 15Robarts Clinical Trials, London, ON, Canada

P632: Allogenic hPDMSCs gelatum in the treatment of perianal fistulas in patients with Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Tang*1, X. Wu1, X. Cao2, X. Gao1, P. Lan1

1The Sixth Affiliated Hospital of Sun Yat-sen University, Department of Colorectal Surgery, Guangzhou, China, 2Tianjin Medical University General Hospital, Tianjin Medical University, Department of Gastroenterology and Hepatology, Tianjin, China

P633: Harmonisation of quality of care in an IBD centre impacts disease outcomes: importance of structure and process indicators

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Reinglas*1, S. Restellini2, L. Gonczi3, Z. Kurti3, S. Nene1, R. Kohen1, W. Afif1, T. Bessissow1, G. Wild1, E. Seidman1, A. Bitton1, P. Lakatos1

1McGill University Health Center, Division of Gastroenterology, Montreal, Canada, 2Geneva’s University Hospitals and University of Geneva, Division of Gastroenterology and Hepatology, Geneva, Switzerland, 3Semmelweis University, First Department of Internal Medicine, Budapest, Hungary

P634: Real-world data on the efficacy and safety of vedolizumab therapy in patients with inflammatory bowel disease: a retrospective nation-wide cohort study in Singapore

ECCO '19 Copenhagen

Year: 2019
Authors:

A. T-M. Gan*1, W. P-W. Chan1, K. L. Ling1,2, L. J. Hartono3, D. E. Ong3, M. Gowans3, H. Lin4, W. C. Lim4, M. T-K. Tan5, J. P-L. Ong5, B. J. Schwender1, S. C. Kong1, W. C. Ong1, T. G. Lim1, S. W. Chuah6, C. J. Ooi6, H. H. Shim1

1Singapore General Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore, 2Mount Elizabeth Hospital, Singapore, Singapore, 3National University Hospital, Division of Gastroenterology and Hepatology, Singapore, Singapore, 4Tan Tock Seng Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore, 5Changi General Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore, 6Gleneagles Hospital, Singapore, Singapore

P635: Carriage of the HLA-DQA1*05 allele is associated with a high risk of loss of response to infliximab in patients with inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Guardiola*1,2, L. Rodriguez Alonso1, E. Santacana3, A. Padró4, K. Serra1, N. Padullés3, A. Ruiz-Cerulla1, P. Gilabert1, C. Arajol1, G. Ibañez-Sanz1, B. Camps1, J. Orobitg1, A. Serracarbasa1, L. de la Peña1, A. Berrozpe1, F. Rodriguez Moranta1

1Hospital Universitari de Bellvitge, Gastroenterology, L’Hospitalet de Llobregat, Spain, 2Universitat de Barcelona, Barcelona, Spain, 3Hospital Universitari de Bellvitge, Pharmacy, L’Hospitalet de Llobregat, Spain, 4Hospital Universitari de Bellvitge, Clinical Genetics Laboratory, L’Hospitalet de Llobregat, Spain

P636: Impact of anti-TNF treatment on extra-intestinal manifestations in patients with inflammatory bowel disease: real-world data in Germany

ECCO '19 Copenhagen

Year: 2019
Authors:

D. Bettenworth*1, W-J. Lee2, R. S. Clark2, S. Rath3, M. Yang4, A. Bensimon4, S. Vavricka5

1University Hospital Munster, Department of Medicine B - Gastroenterology and Hepatology, Munster, Germany, 2AbbVie Inc., North Chicago, United States, 3AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 4Analysis Group, Inc., Boston, USA, 5Triemli Hospital, Zentrum fur Gastroenterologie und Hepatologie, Department of Medicine, Division of Gastroenterology, Zurich, Switzerland

P637: MMP-2 and -8 degraded and citrullinated-vimentin (VICM) correlates to disease activity in inflammatory bowel diseases

ECCO '19 Copenhagen

Year: 2019
Authors:

L. Godskesen1, M. Lindholm2, J. Høg Mortensen2, A. Krag1, T. Manon-Jensen2, M. Karsdal2, J. Kjeldsen1

1Odense University Hospital, Department of Medical Gastroenterology, Odense, Denmark, 2Nordic Bioscience, Biomarkers and Research, Herlev, Denmark

P638: BMS-986165, an oral selective tyrosine kinase 2 (TYK2) inhibitor, does not affect the pharmacokinetics of methotrexate in healthy subjects

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Chimalakonda*1, J. Jones III2, R. Dockens1, J. Throup1, S. Banerjee1, I. Girgis1

1Bristol-Myers Squibb, Princeton, United States, 2PRA Health Sciences, Blue Bell, United States

P639: Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?

ECCO '19 Copenhagen

Year: 2019
Authors:

E. Theodoraki*1, E. Orfanoudaki1, K. Foteinogiannopoulou1, E. Legaki2, M. Gazouli2, I. Koutroubakis1

1University Hospital of Heraklion, Gastroenterology Department, Heraklion, Greece, 2Laboratory of Biology, Medical School, National and Kapodistrian University of Athens, Athens, Greece

P640: Evaluation of dietetic services and the impact of diet on disease activity for patients with inflammatory bowel disease at Imperial College Healthcare NHS Trust

ECCO '19 Copenhagen

Year: 2019
Authors:

H. Sandhar*1, N. Direkze2, S. Peake2

1Imperial College London, Faculty of Medicine, London, UK, 2Imperial College Healthcare NHS Trust, Gastroenterology, London, UK

P641: Ustekinumab efficiency as a higher-line therapy in association with serum levels in patients with Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Kolar*1, K. Pudilova1, M. Bortlik1,2,3, D. Duricova1, K. Malickova1,4, M. Lukas1, V. Hruba1, N. Machkova1, R. Vanickova1, K. Mitrova1, M. Vasatko1, M. Lukas1,4

1ISCARE I.V.F. a.s., IBD Clinical and Research Centre, Prague, Czech Republic, 2Military University Hospital and First Faculty of Medicine, Charles University, Department of Internal Medicine, Prague, Czech Republic, 3Institute of Pharmacology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 4Institute of Medical Biochemistry and Laboratory Medicine, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic